secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENDRA Life Sciences Inc. (NDRA)
CIK:        0001681682
Form:       8-K
Filed at:   2026-10-01T21:18:56+00:00
Accession:  0001213900-26-105899
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

ENDRA amends ASPI merger; Renergen loan capacity to rise to $200M, min cash set at $3.8M
--------------------------------------------------------------------------------

- First Amendment dated Oct 1, 2026 to the June 25, 2026 deal under which Kruger Merger Sub (ENDRA) merges into Noble Africa LLC, surviving as a wholly-owned ENDRA subsidiary.
- Minimum cash closing condition now $3,800,002.59, reduced by cumulative IRA Payments under ENDRA's July 15, 2026 investor relations agreement with RedChip Companies.
- Renergen's borrowing capacity from ASPI rises from $80M to up to $120M via a fifth addendum to the May 19, 2025 term loan, and to up to $200M via a sixth addendum due at or before closing.
- ENDRA and LHE LNG Holdings amended the May 27, 2026 warrants to remove the 4.99% beneficial ownership cap; they cover 511,541 pre-funded shares at $0.0001 and 1,156,774 shares at $6.57.
- Classified board dropped: the post-closing ENDRA board will include the Company CEO, at least five non-executive directors designated by ASPI/Noble, and one ENDRA-designated director.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1681682/000121390026105899/0001213900-26-105899-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1681682/000121390026105899/ea0307011-8k425_endra.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-105899

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer